Table 2.
Patients characteristics
| (a) Ages of patients included in the study | |
|---|---|
| N (%) | |
| Age (year) | |
| < 40 | 5 (3.1%) |
| 40–49 | 71 (47.3%) |
| 50–59 | 59 (36.9%) |
| 60–69 | 16 (10%) |
| 70 + | 9 (5.6%) |
| < 50 | 76 (47.5%) |
| 50 + | 84 (52.5%) |
| (b) Patients characteristicsa (N = 160): Histology, receptor status, and staging | |
|---|---|
| N (%) | |
| pT (ypT) | |
| 0 | 4 (2.5) |
| 1mi | 2 (1.2) |
| 1a | 24 (15.0) |
| 1b | 66 (41.2) |
| 1c | 2 (1.2) |
| 2 | 46 (28.7) |
| 3 | 14 (8.8) |
| 4 | 1 (0.6) |
| Missing | 1 (0.6) |
| pN | |
| 0 | 83 (51.9) |
| 1 | 42 (26.2) |
| 2 | 12 (7.5) |
| 3 | 16 (10.0) |
| X | 6 (3.7) |
| Missing | 1 (0.6) |
| Grade | |
| G1 | 27 (16.9) |
| G2 | 70 (43.7) |
| G3 | 57 (35.6) |
| Missingb | 6 (3.7) |
| ER | |
| ER+ | 95 |
| ER− | 65 |
| Missingb | 0 |
| PgR | |
| PgR+ | 95 |
| PgR− | 65 |
| Missingb | 0 |
| Ki 67 | |
| Ki 67 low (< 20%) | 88 |
| Ki 67 high (> 20%) | 70 |
| Missingb | 2 |
| Her2/neu | |
| Her2/neu + | 90 |
| Her2/neu- | 67 |
| Missingb | 3 |
aFinal characteristics of the worst nodule when more than one present per patient
bOr not evaluable